Revealing Cancer Dependencies and Determinants of Therapeutic Response Using CRISPR

View the Webinar

Presented by

Luke Gilbert

University of California, San Francisco

Covered in this Webinar

How functional genomic screening using CRISPR can be used to identify new strategies for treatment of cancers

Identification of genes required for Androgen receptor driven prostate cancer

Determinants of response to new drugs and combination therapies

Strategies for targeting loss-of-function driver mutations such as TP53-mutant acute myeloid leukaemia

Genomics and functional genomic approaches are needed to identify new strategies for the treatment of aggressive cancers. We use synthetic biology to build new innovative tools for editing the epigenome and driving innovation in functional genomics. Our efforts are focused on utilizing our CRISPR expertise to tackle big problems such as drug resistance in prostate cancer, leukemia, and lung cancer. We use genome-scale screens and genetic interaction mapping to identify the genetic and epigenetic causes underlying why some patients are cured and others are not by cancer therapy.

Share your details to Watch the Webinar

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

Revealing Cancer Dependencies and Determinants of Therapeutic Response Using CRISPR

Related Resources

A Platform to Create High-Throughput Uniform Cloned Oligo Pools for CRISPR Screens

Decoding transcriptional regulation using massively parallel reporter assays and Twist Oligo Pools

Scalable and combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted seq